Form 4: Nuvalent's Chief Legal Officer, Deborah Ann Miller, Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 16, 2024, Deborah Ann Miller, the Chief Legal Officer of Nuvalent, Inc., executed a stock option to purchase 8,000 shares of Class A Common Stock at a price of $18.93 per share.
- Simultaneously, Miller sold a total of 8,000 shares of Class A Common Stock in multiple transactions at prices ranging from $93.22 to $102 per share.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 27, 2023.
- Following these transactions, Miller directly owns 33,300 shares of Nuvalent's Class A Common Stock and holds options for 71,000 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock transactions by an officer under a pre-arranged plan. There's no indication of unusual activity or cause for alarm.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan is a common practice to allow insiders to sell shares without raising concerns about trading on non-public information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by a company officer, but the existence of a 10b5-1 plan mitigates concerns.
Key Dates
| Date | Description |
|---|---|
| December 27, 2023 | Date the reporting person adopted the Rule 10b5-1 trading plan |
| January 4, 2023 | 25% of the shares vested on this date. |
| September 16, 2024 | Date of the reported transactions (option exercise and stock sales) |
| September 18, 2024 | Date of signature for the Form 4 filing |
| January 4, 2032 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.